Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma

Table 2 Univariate analysis results

Variable	Patients (n)	Median survival time (mo)	χ2	P value
BCLC stage
A	4	36 (range: 25-60)
B	60	25 (range: 3-96)
C	22	5 (range: 2-40)	29.765	0
Tumor size
Small HCC	13	50 (range: 26-63)
Nodular type	32	29 (range: 13-96)
Massive type	11	12 (range: 4-60)
Huge type	30	8 (range: 2-43)	14.999	0
PVTT
None	67	25 (range: 3-96)
Branch type	10	5 (range: 2-40)
Trunk type	9	4 (range: 3-6)	43.086	0
Child-Pugh class
A	62	30 (range: 4-96)
B	24	7 (range: 2-19)	51.820	0
ECOG score
0	11	50 (range: 30-96)
1	45	29 (range: 5-84)
≥ 2	30	8 (range: 2-32)	28.660	0
AVF
Without	68	25 (range: 3-96)
With	18	5 (range: 2-40)	29.791	0
MWA times
Once	35	14 (range: 2-60)
Twice	24	20 (range: 3-60)
≥ Triple	27	32 (range: 8-96)	12.920	0.002
Targeted drug
Without	22	6 (range: 2-60)
With	64	24 (range: 5-96)	10.901	0.001

BCLC: Barcelona Clinic Liver Cancer; HCC: Hepatocellular carcinoma; PVTT: Portal vein tumor thrombus; ECOG: Eastern Cooperative Oncology Group; AVF: Arterio-venous fistula; MWA: Microwave ablation.